Immunotherapy with trastuzumab, in combination with chemotherapy, improves disease-free survival in patients with early-stage HER2-positive breast cancer [1,2,3] and increases time to disease progression in those with metastatic-stage cancer [4,5]. Here, ERBB2 is linked to breast cancer.